JP2023551249A5 - - Google Patents

Info

Publication number
JP2023551249A5
JP2023551249A5 JP2023531700A JP2023531700A JP2023551249A5 JP 2023551249 A5 JP2023551249 A5 JP 2023551249A5 JP 2023531700 A JP2023531700 A JP 2023531700A JP 2023531700 A JP2023531700 A JP 2023531700A JP 2023551249 A5 JP2023551249 A5 JP 2023551249A5
Authority
JP
Japan
Prior art keywords
concentration
alkylenyl
pharmaceutical composition
controlled
release pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531700A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551249A (ja
Filing date
Publication date
Priority claimed from CU2020000087A external-priority patent/CU24720B1/es
Application filed filed Critical
Publication of JP2023551249A publication Critical patent/JP2023551249A/ja
Publication of JP2023551249A5 publication Critical patent/JP2023551249A5/ja
Pending legal-status Critical Current

Links

JP2023531700A 2020-11-24 2021-11-18 アルツハイマー病の治療のためのマルチターゲット治療薬としてのナフタレン誘導体の医薬組成物 Pending JP2023551249A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2020000087A CU24720B1 (es) 2020-11-24 2020-11-24 Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
CU2020-0087 2020-11-24
PCT/CU2021/050012 WO2022111742A1 (es) 2020-11-24 2021-11-18 Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer

Publications (2)

Publication Number Publication Date
JP2023551249A JP2023551249A (ja) 2023-12-07
JP2023551249A5 true JP2023551249A5 (cg-RX-API-DMAC7.html) 2024-11-25

Family

ID=80034851

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531700A Pending JP2023551249A (ja) 2020-11-24 2021-11-18 アルツハイマー病の治療のためのマルチターゲット治療薬としてのナフタレン誘導体の医薬組成物

Country Status (10)

Country Link
US (1) US20240299334A1 (cg-RX-API-DMAC7.html)
EP (1) EP4252749A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023551249A (cg-RX-API-DMAC7.html)
KR (1) KR20230118112A (cg-RX-API-DMAC7.html)
CN (1) CN116829137A (cg-RX-API-DMAC7.html)
AU (1) AU2021388673A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200071A1 (cg-RX-API-DMAC7.html)
CU (1) CU24720B1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006072A (cg-RX-API-DMAC7.html)
WO (1) WO2022111742A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119523898A (zh) * 2024-12-02 2025-02-28 肇庆学院 多靶点药物的经鼻给药制剂及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US20040254146A1 (en) 2002-05-21 2004-12-16 Nastech Pharmaceutical Company Inc. Carboxylate salts of galantamine and their pharmaceutical use
US20030225031A1 (en) 2002-05-21 2003-12-04 Quay Steven C. Administration of acetylcholinesterase inhibitors to the cerebral spinal fluid
CN1621039A (zh) 2003-11-25 2005-06-01 上海医药工业研究院 石杉碱甲及其衍生物或其盐的经鼻脑靶向制剂
EP1715843A1 (en) 2004-01-29 2006-11-02 Neuromolecular Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadph-inhibitor for the treatment of central nervous system-related conditions
WO2006009769A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
US8058291B2 (en) 2005-04-06 2011-11-15 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of CNS-related conditions
EP2623099A1 (en) 2004-11-24 2013-08-07 Neuromolecular Pharmaceuticals, Inc Composition and method for treating neurological disease
WO2007002497A1 (en) 2005-06-23 2007-01-04 Envivo Pharmaceuticals, Inc. Method of treating neurological disorders using clotrimazole and derivatives thereof
US20070141148A1 (en) * 2005-11-30 2007-06-21 Merz Pharma Gmbh & Co. Kgaa Neramexane MR matrix tablet
US7745670B2 (en) * 2008-06-27 2010-06-29 Codman & Shurtleff, Inc. Curcumin-Resveratrol hybrid molecule
CU23844B1 (es) 2009-04-17 2012-10-15 Ct De Neurociencias De Cuba Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer
CU20130027A7 (es) * 2013-02-28 2014-10-30 Ct De Neurociencias De Cuba Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales
CU24583B1 (es) * 2018-11-06 2022-02-04 Centro De Neurociencias De Cuba Nanopartículas de óxido metálicos conjugados con derivados de naftaleno como agentes de contrastes para la detección de placas amiloides por resonancia magnética (mri)

Similar Documents

Publication Publication Date Title
CN1137684C (zh) 用碱性试剂稳定的药物组合物
EP2760821B1 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
US10786507B2 (en) Pharmaceutical composition containing JAK kinase inhibitor or pharmaceutically acceptable salt thereof
US20090208583A1 (en) Tablets comprising candesartan cilexetil
KR101257919B1 (ko) 콜린 알포세레이트 또는 이의 약학적으로 허용되는 염을 포함하는 경구용 고형 제제 및 이의 제조방법
NO20066041L (no) Anvendelse av substituerte kinolinderivater for behandlingen og legemiddelresistente mykobakterielle sykdommer
MXPA05005667A (es) Dispersiones solidas que comprenden un farmaco higroscopico y/o delicuescente.
JP2022123032A (ja) エダラボン医薬組成物
JP2003535895A5 (cg-RX-API-DMAC7.html)
BG65472B1 (bg) Използване на саредутант и неговите фармацевтичноприемливи соли за приготвяне на лекарствено средство за използване за лечение или профилактика на голямо депресивно разтройство
JP2019123703A (ja) ダサチニブを有効成分とする医薬錠剤及びその製造方法
JP2017048174A (ja) 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤
SK100998A3 (en) Pharmaceutical compositions of cilansetron stabilized against racemisation
US20080260785A1 (en) Paroxetine compositions
JP2007197410A (ja) フィルムコーティング錠
US20060020040A1 (en) Bupropion hydrochloride solid dosage forms
JP2002284679A (ja) 安定な甲状腺ホルモン含有固形製剤組成物
JP2000336032A (ja) ピペラジンアセトアミド誘導体を含有する徐放性経口医薬品組成物
JP3597823B2 (ja) 固形製剤
US20200237744A1 (en) Antimicrobial Compositions with Effervescent Agents
WO2022111742A4 (es) Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
JP2017095441A (ja) アジルサルタン含有医薬組成物、医薬組成物におけるアジルサルタンの安定化方法、及びアジルサルタンの安定化剤
AU2017251803B2 (en) Choline salt of an anti-inflammatory substituted cyclobutenedione compound
KR20070102563A (ko) 정신병치료제를 함유하는 조절방출형 조성물
JP2024539116A5 (cg-RX-API-DMAC7.html)